ResMed Ansoff Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Make Smarter Expansion Decisions with the Full Report
This ResMed Amsoff Matrix Analysis gives a structured view of ResMed's growth options across market penetration, market development, product development, and diversification. What you see here is a real preview of the actual report, so you can review the content before buying. Purchase the full version to get the complete ready-to-use analysis.
Market Penetration
AirSense 11 upgrade cycle
ResMed used the 2021 AirSense 11 launch to pull older CPAP users into a higher-price unit without changing the sleep-apnea end market. In FY2025, ResMed generated about $5.0 billion of revenue, with Devices still its largest mix, so upgrades matter for both share and ASP. Same clinics and DMEs can keep selling inside the same channel, which makes this the cleanest market penetration lever.
Mask attach-rate expansion
ResMed's AirFit and AirTouch masks sit behind device sales as a recurring consumable layer; ResMed reported FY2025 revenue of $5.1 billion. Masks are often replaced every 6 to 12 months, so a good fit can drive repeat pull-through and raise lifetime value. Better fit also cuts abandonment, helping ResMed keep users from rival mask brands.
Connected adherence tools
ResMed's connected adherence tools, myAir for patients and AirView for providers, extend the sale into a data loop that supports refills, follow-up, and long-term adherence. In FY2025, ResMed reported about $5.1 billion in revenue, and this digital stack helps keep patients visible after setup. Once therapy is live, the linked data makes it harder for rivals to displace ResMed without disrupting adherence data and provider workflow.
Broad channel reach
ResMed's market penetration is powered by broad channel reach across 140+ countries, with sales through DMEs, sleep clinics, hospitals, and digital channels. In FY2025, revenue reached about $5.1 billion, showing how this distribution mix keeps core devices and masks in front of more accounts inside each market. That is a channel-led advantage: it helps ResMed sell the same products into more sites of care, not rely on new-product launches.
- 140+ countries
- FY2025 revenue: about $5.1 billion
- Distribution, not product novelty
Portable CPAP niche
ResMed's portable CPAP niche, led by AirMini and other travel-friendly systems, targets users who want a smaller device without switching away from CPAP or APAP therapy. That helps ResMed win incremental share from convenience-driven buyers and keeps pricing premium in the same sleep apnea market.
In FY2025, ResMed generated about US$5.1 billion in revenue, showing it can monetize this high-margin position at scale. The portable segment adds a clear upgrade path for existing patients, so it lifts share without needing a new therapy category.
ResMed Grows by Deepening Sleep-Apnea Use, Not Expanding Markets
ResMed's market penetration in FY2025 came from deeper use of its core sleep-apnea stack, not new markets: devices, masks, and digital adherence tools all helped lift repeat sales inside the same therapy base.
| FY2025 metric | Value |
|---|---|
| Revenue | about $5.1 billion |
| Reach | 140+ countries |
| Growth lever | Upgrades, refills, adherence |
That mix keeps ResMed in front of DMEs, clinics, and patients, so each account can generate more lifetime value without changing the end market.
What is included in the product
Detailed Word Document
Editable Excel File
Market Development
140-plus-country rollout
ResMed can extend its CPAP, mask, and ventilator line into 140+ markets, especially APAC, Latin America, and EMEA, where the same sleep-apnea and respiratory needs already exist. FY2025 revenue was about $5.1 billion, and this scale gives ResMed room to grow by widening channel access and reimbursement, not by changing the core product set. The main test is local payer coverage and distributor reach, but the global disease base makes geographic expansion a long runway.
Undiagnosed apnea screening
ResMed's FY2025 revenue was about $5.1 billion, and growth still depends on turning more of the huge undiagnosed sleep apnea pool into treated patients. Home sleep testing and tele-diagnosis cut the lab-only bottleneck, so the same masks, devices, and software reach a wider market. That is classic market development: the product stays the same, but access expands and conversion rises.
COPD home-care transition
ResMed can extend its existing ventilators and respiratory devices from sleep clinics into COPD home care and post-acute settings, widening its addressable market. In 2025, about 16 million U.S. adults report COPD, and 65+ adults are 18.6% of the U.S. population, supporting home-based demand. Hospital bed pressure also keeps care shifting home.
DACH software expansion
EDIFOX DAN gives ResMed a clean entry into Germany, Austria, and Switzerland, so its workflow software can move into a larger German-speaking home-care base without changing the core stack.
This is a true geographic expansion play: ResMed reported FY2025 revenue of about $5.0 billion, and DACH adds a richer route to scale software across more care sites.
The upside is deeper use of the same platform in adjacent settings, not a new product reset.
Digital and direct channels
ResMed uses digital and direct channels to reach patients who never enter a sleep lab, which fits market development because it expands demand beyond old referral paths. In fiscal 2025, ResMed reported about $5.1 billion in revenue, showing the scale of its connected-device and app-led funnel.
Its cloud-linked devices and patient apps help educate, onboard, and keep users engaged, so conversion can rise even where sleep-specialist access is thin. That matters most in weak-referral markets, where e-commerce and direct patient education can shorten the path from screening to therapy.
ResMed's Growth Engine: Global Reach, Digital Channels, Bigger Sleep-Apnea Access
ResMed's market development play is geographic and channel expansion: sell the same sleep-apnea and respiratory products into 140+ markets, with FY2025 revenue of about $5.1 billion. Growth comes from wider payer coverage, distributor reach, and direct-to-patient digital channels, not new hardware. Home sleep testing and tele-diagnosis also help convert more of the undiagnosed pool.
| FY2025 | Data |
|---|---|
| Revenue | $5.1B |
| Markets | 140+ |
Get Your Copy
ResMed Reference Sources
This is the same ResMed Amsoff Matrix analysis document included in your download. The preview below is taken directly from the full report, so what you see is what you'll receive after purchase.
Product Development
AirSense 11 platform
ResMed's AirSense 11 platform, launched in 2021, is the clearest product-development move in sleep apnea because it keeps the same therapy category while improving setup, app links, and patient coaching. ResMed said FY2025 revenue was about US$5.1 billion, and connected-device scale matters because it helps keep users inside the ResMed ecosystem instead of switching brands. That matters in a market where CPAP adherence still drives repeat supply sales and long-term recurring revenue.
Mask redesign cadence
ResMed's mask redesign cadence is a low-risk way to grow in an existing market: its AirFit and AirTouch lines keep improving through new cushion materials, fit geometry, and more sizes, which helps comfort and adherence. In FY2025, ResMed reported about $5.1 billion in revenue and a 59.4% non-GAAP gross margin, showing the value of high-margin consumables tied to the installed base. Small mask tweaks can lift repeat use without the cost and risk of a new platform.
myAir and AirView upgrades
ResMed's myAir and AirView upgrades deepen patient coaching and provider analytics in two linked platforms, making the device harder to replace. Better alerts, adherence tracking, and data visibility can lift therapy persistence and support more visits and refills. In FY2025, ResMed reported revenue of about $5.1 billion, and these software layers help protect and grow that base by raising the value of each sleep device sold.
Ventilation and COPD improvements
ResMed's FY2025 revenue was about $5.1 billion, and its product set now goes beyond CPAP into noninvasive ventilation and other respiratory support.
That matters because features aimed at COPD and more severe disease states let ResMed serve patients higher on the care ladder without leaving its core respiratory market.
So this product development path supports broader use, deeper customer need, and a larger recurring device-and-mask base.
Software feature depth
ResMed deepens software feature depth by adding new workflows, billing tools, and care-coordination functions in matrixCare and MEDIFOX DAN for existing provider users. In fiscal 2025, ResMed reported revenue of $5.15 billion, and this kind of product expansion helps lift revenue per account instead of relying on new-market entry. It also supports stickier customer relationships and higher switching costs.
ResMed's FY2025 upgrades boosted growth, margin and recurring sales
ResMed's product development in FY2025 stayed inside its core sleep and respiratory market, but added value through AirSense 11, AirFit and AirTouch mask upgrades, and stronger myAir and AirView software. FY2025 revenue was US$5.15 billion, and non-GAAP gross margin was 59.4%, showing the payoff from higher-value devices and consumables. These moves raise adherence, deepen switching costs, and support recurring sales.
| FY2025 metric | Value |
|---|---|
| Revenue | US$5.15 billion |
| Non-GAAP gross margin | 59.4% |
| Core move | Device, mask, and software upgrades |
Diversification
MatrixCare deal
ResMed paid $750 million for MatrixCare in 2019, and that moved it into US long-term and post-acute care software. In FY2025, ResMed reported revenue of $5.1 billion, so MatrixCare sits inside a much larger health-tech base. This is true diversification: devices sell to patients and providers, while MatrixCare sells SaaS to care facilities. It also adds recurring software revenue, which is steadier than one-time hardware sales.
Propeller Health acquisition
ResMed bought Propeller Health in 2018 for about $225 million, a clear new-product, new-market move in Ansoff Matrix terms. It pushed ResMed from devices into connected therapy for asthma and COPD, widening the digital respiratory care platform. In FY2025, ResMed reported revenue of $5.15 billion, showing how the portfolio now blends hardware with recurring digital and service-linked care.
MEDIFOX DAN in DACH
MEDIFOX DAN gives ResMed a 3-country DACH foothold in care-management software, so it adds geography and product breadth beyond masks and devices. That matters as care shifts from facilities to homes: ResMed reported FY2025 revenue of $5.1 billion, with Software as a Service helping diversify cash flow. In Germany, Austria, and Switzerland, that software layer can help ResMed reach home-care workflows, not just therapy hardware.
Workflow and billing software
ResMed's workflow and billing software can monetize scheduling, documentation, and reimbursement, so revenue is not tied only to device shipments. That mix improves revenue quality and reduces dependence on replacement cycles that can swing with CPAP demand. It also makes ResMed more embedded in provider operations, which can lift stickiness across its 2025 base of millions of patients and sleep-apnea users.
Subscription mix shift
ResMed's subscription mix shift moves more revenue into aaS and recurring software fees, which cuts volatility versus one-time device sales. That matters because these contracts often run 12 to 24 months, so software can stack and renew across cycles instead of resetting each quarter. The strategic goal is a more balanced revenue mix by 2026, with FY2025 already showing the benefit of steadier, recurring cash flow.
ResMed's software bets are strengthening its revenue mix
ResMed's diversification in the Ansoff Matrix is clear: MatrixCare, Propeller Health, and MEDIFOX DAN moved ResMed beyond masks and devices into care software, connected therapy, and DACH workflows. In FY2025, ResMed reported revenue of $5.15 billion, with recurring software fees helping soften hardware cycles. That mix lifts revenue quality and broadens geographic reach.
| FY2025 item | Value |
|---|---|
| ResMed revenue | $5.15 billion |
| MatrixCare deal | $750 million |
| Propeller Health deal | About $225 million |
Frequently Asked Questions
ResMed increases share by upgrading installed CPAP users, expanding mask attach rates, and using connected monitoring to keep patients on therapy. The 2021 AirSense 11 launch, 140-plus-country distribution, and 6 to 12 month mask replacement cycles all support this. The result is higher wallet share without changing the core sleep apnea market.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.